Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
CAPHRA Urges Policymakers to Expand the Tobacco Cessation Toolkit
CAPHRA is urging policymakers to broaden the tobacco‑cessation toolkit by adding regulated, lower‑risk nicotine products alongside traditional nicotine‑replacement therapies. The organization argues that a diversified, evidence‑based approach can accommodate varied quitting pathways, cultural contexts, and product preferences. By expanding options, CAPHRA expects fewer smokers, reduced preventable deaths, and lower health‑system expenditures. The call emphasizes measurable public‑health impact over ideological debates.
On the Nature of AI Fallibility
A BMJ letter argues that AI’s fallibility should be judged against its net benefit rather than an impossible standard of infallibility. The author notes AI can serve as an always‑available clinical confidante, mitigating human fatigue, bias, and limited availability. He...
Why Artificial Intelligence Displacement Threatens Medical Specialties
Artificial intelligence is poised to reshape medicine in a tiered fashion, with pattern‑recognition specialties such as radiology and pathology facing functional AI parity within five to ten years. Protocol‑driven fields like cardiology and endocrinology will see AI‑managed routine care in...
Gene Signature Swiftly Distinguishes Ebola From Other Illnesses
A newly identified gene pattern enables rapid and accurate distinction of Ebola infection from other diseases, offering potential for improved diagnostic tests in outbreak scenarios. genomics
StockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares
Erasca (NASDAQ: ERAS) saw its shares plunge 53% after disclosing a patient death linked to its pan‑RAS drug ERAS‑0015 and a patent infringement claim from rival Revolution Medicine. The company reported unconfirmed overall response rates of 62%‑75% in KRAS G12X...
Natural Daylight in the Office Helps People with Type 2 Diabetes Control Blood Sugar
Researchers at the German Diabetes Center found that office workers with type‑2 diabetes who spent their daytime in natural daylight spent a larger share of the day (51 %) within a healthy glucose range, compared with 43 % under standard artificial lighting....
Wall-Mount 60 W Supplies Save Installation Space
XP Power has launched the AMF60 series, a family of 60 W wall‑mount AC‑DC power supplies housed in an IP42 sealed enclosure. The supplies deliver 12 V, 15 V, 19 V and 24 V outputs up to 5 A, accept 80‑264 VAC input, and feature interchangeable US,...
Re: Limit Use of Nasal Decongestant Sprays to Five Days, UK Regulator Says
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued new guidance limiting the use of over‑the‑counter nasal decongestant sprays containing xylometazoline or oxymetazoline to a maximum of five days. The advisory reiterates long‑standing clinical warnings that prolonged use...
Wearables Transform Clinical Trials with Continuous Real‑World Data
Delighted to share details on an exciting forum that we are hosting here at the Querrey Simpson Institute for Bioelectronics at @NorthwesternU — Advanced Wearable Sensors and the Future of Clinical Trials — on June 24, 2026, at the...
In a Reversal, Doctors From Countries Under Trump’s Travel Ban Are Allowed to Stay in U.S.
The Department of Homeland Security has lifted the travel‑ban restriction on physicians from the 39 countries targeted by the Trump administration, allowing visa extensions, work permits and green cards to be processed again. The change was announced quietly on the...
Are NHS GPs the Last Line of Defence?
The blog argues that NHS general practitioners are more than gatekeepers—they are the lynchpins of patient safety. Typical GP consultations last about seven minutes, forcing doctors to triage single symptoms quickly. This model functions only when staffing, time, and funding...
DNA‑Based Gene Therapy Slashes LDL Cholesterol by 47% in Mice, Bypassing Statins
Researchers at the University of Barcelona and the University of Oregon reported that a DNA‑based molecule lowered LDL cholesterol by about 47% in mice after a single injection. The approach silences the PCSK9 gene without the muscle and liver side...
Parexel Acquires Vitrana to Boost AI-Driven Patient Safety Platform
Parexel announced the acquisition of Vitrana, an AI‑enabled pharmacovigilance technology provider, to create a single‑partner model for safety services and software. Financial terms were not disclosed, but the deal expands Parexel’s AI capabilities and promises faster, more compliant adverse‑event processing...
Brain Complexity Enhances Premature Newborns’ Maturity Evaluation
Researchers have demonstrated that measuring brain signal complexity provides a reliable indicator of physiological maturity in premature newborns. Using high‑density EEG and advanced signal‑processing algorithms, the study linked specific complexity patterns to gestational age and future neurodevelopmental trajectories. The approach...
Wearable-Derived Metrics May Monitor Treatment Response in IBD
Researchers presented data at Digestive Disease Week showing that sleep metrics captured by the Oura Ring can differentiate patients with inflammatory bowel disease who respond to biologic therapy from those who do not. In a 14‑week study of 60 adults,...
Pfizer, Arvinas Win FDA Nod for VEPPANU, First PROTAC Cancer Drug
Pfizer and Arvinas have secured U.S. FDA approval for VEPPANU (vepdegestrant), the first orally bioavailable PROTAC drug, targeting estrogen‑receptor positive, HER2‑negative, ESR1‑mutated advanced breast cancer after endocrine therapy failure. The decision validates the targeted protein degradation platform while raising questions...
Sun Pharma to Acquire Organon for $11.75 Bn, Marking India's Largest Overseas Pharma Deal
Sun Pharmaceutical Industries announced an all‑cash purchase of Organon & Co. for $11.75 bn, paying $14 per share—a 24% premium to the prior close. The transaction, the largest overseas pharma acquisition by an Indian company, will reshape financing structures and draw...
IBD Mortality Worsened for All in Pandemic, Widened Disparities
A new analysis of CDC death records shows that inflammatory bowel disease (IBD) mortality rose nationally during the COVID‑19 pandemic, increasing from 0.93 to 1.17 deaths per 100,000 people. Both white and Black patients experienced higher death rates, but the...
Children’s Mercy Hospital Launches $1 B Pediatric Tower to Boost Capacity
Children’s Mercy Hospital revealed a more‑than‑$1 billion plan for a new acute‑care tower that will increase overall capacity by 25‑30%. The nonprofit, which posted $2 billion in revenue and $418.5 million in excess revenue in 2025, must now devise a financing strategy that...
Major Depression Remains ‘Usually Undertreated’ in Rheumatology
Major depression is prevalent among rheumatology patients and frequently remains untreated, even after diagnosis, according to Dr. Michael R. Clark at the Congress of Clinical Rheumatology East. About 60% of patients with depression report concurrent pain, and longitudinal data show...
Review Flags Neurotoxic Risks of Silver Nanoparticles in Rodent Studies
Researchers from Çanakkale Onsekiz Mart University and University Montpellier published a review on 29 April 2026 that links silver nanoparticle exposure to multiple neurotoxic mechanisms in rodent models. The paper warns that expanding biomedical applications—such as neural implants and drug‑delivery systems—must contend...
Intuitive Surgical’s Da Vinci Platform Powers 580% Stock Surge
Intuitive Surgical’s stock has risen roughly 580% over the past ten years, outpacing the S&P 500’s 240% gain. The surge is anchored in the da Vinci surgical‑robot platform, whose expanding installed base fuels a high‑margin parts, instruments and services business.
Loyal's Canine Longevity Pill Nears Market After FDA Deems Likely Effective
Loyal, the biotech startup founded by Celine Halioua, has moved its canine longevity pill closer to market after the FDA deemed it likely effective in February 2025. The drug, which could add a year to a dog’s healthy lifespan, arrives amid...
The Real Work Starts After a Mental Health Crisis
Emergency physician Dr. Kenneth Scott Burnham recounts his own descent into mental‑health crisis after 23 years of stabilizing patients in the ER. He describes the stark contrast between acute crisis care and the unsupported, confusing period that follows discharge. Burnham...
BofA Keeps Buy on Eli Lilly, Sets $1,133 Target After Strong Q1
Bank of America reaffirmed its Buy rating on Eli Lilly, lifting its price objective to $1,133—about 21% upside—following a first‑quarter that beat sales and earnings expectations. The analyst firm highlighted the drugmaker’s obesity and GLP‑1 momentum and adjusted its valuation...
NYC Community Rallies as Paramedic Faces Cancer Battle
Staten Island paramedic William Negron, a 31‑year veteran of Northwell Staten Island University Hospital, has been diagnosed with liver cancer after tumors were discovered during 2025 bloodwork. He has undergone radiation at Mount Sinai and now faces additional treatment and...
AI Is Starting To Outperform Doctors. Here’s Why Doctors Are Needed Now More Than Ever
Recent studies show artificial‑intelligence models surpassing emergency‑room physicians in diagnostic decision‑making and outpacing radiologists in detecting pancreatic cancer up to three years before clinical presentation. The AI systems achieved higher accuracy by analyzing electronic health records and routine CT scans,...
Redefining Success in Transplant Medicine
In this episode of Signals KOLs, transplant nephrologist Dr. Deirdre Sawinski, industry veteran Steve Risk (SVP Medical Affairs at Veloxys), and patient‑physician Sejal Patel discuss the stagnant long‑term outcomes in kidney transplantation despite excellent short‑term success. They highlight how current...
RESEARCH: NICLOSAMIDE in CANCER and Other Diseases - 2025 Review Paper From Henan, China
A 2025 review paper from Henan, China, evaluates niclosamide—a decades‑old anti‑parasitic—as a repurposed oncology agent. The analysis compiles pre‑clinical data across breast, lung, pancreatic and colorectal cancers, and highlights early‑phase clinical trials showing modest tumor responses. Researchers also discuss formulation...
Liquid Biopsy Predicts Response to Breast Cancer Immunotherapy
Researchers at Vanderbilt-Ingram Cancer Center demonstrated that serial liquid biopsies analyzing peripheral blood RNA can predict response to pembrolizumab in high‑risk early‑stage HER2‑negative breast cancer. The study examined 546 blood samples from 160 patients in the I‑SPY2 trial, showing transcriptional...
Electronics‑Free Smart Lens Monitors Glaucoma and Releases Medication
Researchers have developed a prototype electronics-free smart contact lens that can track glaucoma in real time and deliver drugs in response. https://spectrum.ieee.org/smart-contact-lens-glaucoma-microfluidics
Vaccines, Not Geroscience, Drove Lifespan Gains; GLP‑1s Now Hype
fun facts: class of medicines that have most greatly extended human lifespan: vaccines class of medicines longevity docs are most excited by now: GLP1s did these come from geroscience? they did not by the way, NR didn't come from geroscience either
The Evolving Medical Practice: How Doctors Can Adapt and Prosper In a Changing Environment
Physicians are confronting delayed reimbursements, rising labor and supply costs, and heightened cyber risk. The article proposes three resilience pillars: tighten accounts‑receivable to keep cash flow within a 35‑40‑day window, fortify digital defenses through annual HIPAA risk assessments and multifactor...
Clear Risk Communication Turns Health Info Into Action
Too much health info online, too little clarity? 🤯 How do we communicate risks so people actually understand and act? The new podcast from Bundesinstitut für Risikobewertung breaks down what effective risk communication really means—and why it matters. 🎧 Listen now: https://t.co/eB5nkcmpQ4
Control Life’s Essential 8 to Prevent CVD
Risk Factors Present in Nearly All Patients Who Develop CVD Keeping these factors in check and adhering to the AHA’s Life’s Essential 8, is the best way to prevent CVD, say researchers. https://t.co/YbqEkUmjiK https://t.co/kt6Rmem11c
The Biosimilar Market Isn’t Failing, It’s Finding Its Purpose
The biosimilar market is not collapsing; it is transitioning from a price‑driven scramble to a purpose‑focused strategy. Recent HHS data show that markets become uneconomic once five competitors vie for the same molecule, prompting a shift toward diversified product portfolios....
LLMs Show Minimal Evidence of Improving Health Outcomes
“In summary, there is very little evidence for LLMs benefiting patients or doctors for health outcomes” - Dr. @EricTopol Read his full review here: https://t.co/vHKo35n2BT
AI in Medicine: Overused Without Evidence, Under
It's striking. Both the under- and over-use of AI in medicine, by patients and doctors, for where there's evidence and where it doesn't exist https://t.co/jo7sFACPRp
The AI Funding Divide: Why VCs Will Miss the Next Healthcare Category Kings (And Where CEOs Should Look Instead)
The article warns that venture‑capital firms now rely on large‑language‑model agents to triage thousands of life‑science pitches, a process that amplifies familiar patterns and sidelines truly novel healthcare ideas. This bias, dubbed the “AI Funding Divide,” means breakthrough categories can...
Policy’s Role: Align Private Profit with Public Good
100%. the *job* of policy is to align private profit with public good, not to hope that structural incentives can be talked down
Blood Test May Forecast Alzheimer’s Years Before Symptoms
A new study by researchers at Harvard-affiliated Mass General Brigham has found that a blood test has the potential to predict progression of Alzheimer’s disease ***years before*** symptoms or brain scan changes. https://t.co/WtghaB12r2
FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide
On April 30, 2026 the FDA issued a proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, arguing there is no clinical need for outsourcing facilities to compound these GLP‑1 drugs. The move follows the resolution of...
Sheffield to Launch £1.3 Million 24/7 Walk‑In Mental Health Centre at Gleadless and Heeley
Sheffield Health Partnership announced that a £1.3 million, 24‑hour walk‑in mental health centre will open later this month at Newfield Green, serving Gleadless, Heeley and surrounding areas. The facility is one of six sites in an NHS England pilot aimed at...
New Study Links Omega‑3 Supplements to Faster Cognitive Decline in APOE‑ε4 Carriers
Researchers at China’s Army Medical University analyzed data from more than 800 participants in the Alzheimer’s Disease Neuroimaging Initiative and found that omega‑3 supplement users experienced a faster drop in cognitive scores than non‑users, especially among APOE‑ε4 carriers. The findings...
Jamaica Declares 2026 Child Mental‑Health Month, Launches Nationwide Parenting Programs
Jamaica’s Ministry of Education, Skills, Youth and Information has designated 2026 as Child Mental‑Health Month, rolling out a series of activities aimed at parents, educators and community groups. The initiative, themed “Prioritise Our Children’s Mental Health: Strong Minds, Safer Future,”...
Long‑Term Health Score Outperforms Diet and Exercise in Longevity Prediction
Researchers from the Framingham Heart Study reported that a cumulative health score measured over 25 years predicts lifespan more accurately than any single health snapshot. Participants in the top quartile of the score lived, on average, 7.4 years longer without...
DOJ Deploys West Coast Healthcare Fraud Strike Force to Target $45 Billion in Fraud Schemes
The Justice Department’s National Fraud Enforcement Division announced a new West Coast Healthcare Fraud Strike Force covering Arizona, Nevada and Northern California. The initiative builds on a record of prosecuting over 6,200 defendants who billed $45 billion to federal and private...
FDA Rejects RP1 Melanoma Therapy After Fast‑Track Review
The FDA has denied approval of RP1, an oncolytic immunotherapy for advanced melanoma, despite its breakthrough designation. The agency cited a heterogeneous study population and lack of a control arm, overturning an earlier panel recommendation.
Gene Therapy Gives Deaf Toddlers Hearing After One Injection
Regeneron’s Otarmeni received FDA accelerated approval after an international trial showed toddlers with congenital OTOF‑related deafness responding to a single injection. The study, led by Mass Eye and Ear and Fudan University, recorded measurable hearing in 80% of participants, sparking...
Rethinking Blood Thinners for Atrial Fibrillation Patients
At the American College of Cardiology meeting, a three‑year trial demonstrated that the Watchman left‑atrial‑appendage closure device provides stroke protection comparable to lifelong anticoagulation while causing far fewer bleeding events. The findings challenge the entrenched belief that atrial fibrillation patients...